Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated Melanoma
November 21st 2015Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.
Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response
November 20th 2015Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.
Dr. Sancy Leachman on Helping Patients Identify Melanoma Recurrences
November 19th 2015Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.
Sheri Holmen on Understanding Drivers of Melanoma Metastasis
November 19th 2015Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.